Cockbain et al. studied the effect of the free fatty acid form of eicosapentaenoic acid (EPA-FFA) in patients undergoing liver resection surgery for CRC liver metastases. EPA-FFA was safe and well tolerated; it had no effect on the Ki67 proliferation index, but vascularity was reduced in EPA-naive patients and EPA-FFA had antiangiogenic activity in vitro. Early CRC recurrence rates were similar to those in the placebo group, but overall survival was improved in the 18 months after resection in patients who received EPA-FFA before surgery.